Search

Your search keyword '"Todenhöfer T"' showing total 421 results
Start Over Author "Todenhöfer T"
421 results on '"Todenhöfer T"'

8. Lebensqualität und Patienten-relevante Endpunkte unter Darolutamid-Therapie in der Phase-3-Studie ARASENS

Author

Todenhöfer, T, Fizazi, K, Smith, M, Hussain, M, Saad, F, Sternberg, C, Crawford, E, Aragon-Ching, J, Silke, T, Kapur, S, Mohamed, A, Srinivasan, S, Li, R, Kuss, I, Joensuu, H, Tombal, B, Todenhöfer, T, Fizazi, K, Smith, M, Hussain, M, Saad, F, Sternberg, C, Crawford, E, Aragon-Ching, J, Silke, T, Kapur, S, Mohamed, A, Srinivasan, S, Li, R, Kuss, I, Joensuu, H, and Tombal, B

Published
2023

9. CYCLONE 3: A Phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)

Author

Piulats, J.M., primary, Smith, M., additional, Matsubara, N., additional, Zhang, T., additional, Agarwal, N., additional, Mckay, R.R., additional, Johnston, E., additional, Sherwood, S., additional, Schaverien, C., additional, Fasnacht, N., additional, Lithio, A., additional, Nacerddine, K., additional, and Todenhöfer, T., additional

Published
2023
Full Text
View/download PDF

10. Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma

Author

Gakis, G., Morgan, T.M., Daneshmand, S., Keegan, K.A., Todenhöfer, T., Mischinger, J., Schubert, T., Zaid, H.B., Hrbacek, J., Ali-El-Dein, B., Clayman, R.H., Galland, S., Olugbade, K., Rink, M., Fritsche, H.-M., Burger, M., Chang, S.S., Babjuk, M., Thalmann, G.N., Stenzl, A., and Efstathiou, J.A.

Published
2015
Full Text
View/download PDF

11. Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

Author

Reike, M.J., primary, Ingersoll, M.A., additional, Müller, D.C., additional, Zuiverloon, T.C.M., additional, Strandgaard, T., additional, Kamat, A.M., additional, Williams, S.B., additional, Seiler, R., additional, Todenhöfer, T., additional, Dyrskjøt, L., additional, Nawroth, R., additional, Goebell, P., additional, Schmitz-Dräger, B., additional, Sfakianos, J.P., additional, Meeks, J., additional, Horowitz, A., additional, and Black, P.C., additional

Published
2022
Full Text
View/download PDF

12. 1389P Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)

Author

Linch, M., primary, Ferrario, C., additional, Stoeckle, M., additional, Laguerre, B., additional, Arranz Arija, J.A., additional, Todenhöfer, T., additional, Fong, P.C., additional, Piulats Rodriguez, J.M., additional, Berry, W., additional, Emmenegger, U., additional, Mourey, L., additional, Mar, N., additional, Appleman, L.J., additional, Joshua, A., additional, Conter, H.J., additional, Li, X.T., additional, Schloss, C., additional, Poehlein, C.H., additional, de Bono, J.S., additional, and Yu, E.Y., additional

Published
2022
Full Text
View/download PDF

13. 1423TiP CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)

Author

McKay, R.R., primary, Agarwal, N., additional, Matsubara, N., additional, Piulats Rodriguez, J.M., additional, Smith, M.R., additional, Todenhöfer, T., additional, Zhang, T., additional, Balar, A.V., additional, Schaverien, C., additional, Sherwood, S., additional, Johnston, E., additional, Lithio, A., additional, Nacerddine, K., additional, and Sweeney, C.J., additional

Published
2022
Full Text
View/download PDF

17. KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)–naive patients with metastatic castration-resistant prostate cancer (mCRPC)

Author

Todenhöfer, T., primary, Piulats, J.M., additional, Ferrario, C., additional, Linch, M.D., additional, Stoeckle, M., additional, Laguerre, B., additional, Arranz, J.A., additional, Fong, P.C.C., additional, Berry, W.R., additional, Emmenegger, U., additional, Mourey, L., additional, Mar, N., additional, Appleman, L.J., additional, Joshua, A.M., additional, Conter, H.J., additional, Li, X.T., additional, Schloss, C., additional, Poehlein, C.H., additional, De Bono, J.S., additional, and Yu, E.Y., additional

Published
2022
Full Text
View/download PDF

25. 73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis

Author

Yu, E., primary, Piulats, J.M., additional, Gravis, G., additional, Fong, P., additional, Todenhöfer, T., additional, Laguerre, B., additional, Arranz, J., additional, Oudard, S., additional, Massard, C., additional, Stoeckle, M., additional, Nordquist, L.T., additional, Carles, J., additional, Huang, M., additional, Li, Y., additional, Qiu, P., additional, Poehlein, C.H., additional, Schloss, C., additional, and de Bono, J., additional

Published
2021
Full Text
View/download PDF

26. 612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

Author

Yu, E., primary, Piulats, J.M., additional, Gravis, G., additional, Fong, P.C.C., additional, Todenhöfer, T., additional, Laguerre, B., additional, Arranz Arija, J.A., additional, Oudard, S., additional, Massard, C., additional, Stoeckle, M., additional, Nordquist, L.T., additional, Carles, J., additional, Kolinsky, M.P., additional, Augustin, M., additional, Gurney, H., additional, Tafreshi, A., additional, Li, X.T., additional, Poehlein, C.H., additional, Schloss, C., additional, and de Bono, J.S., additional

Published
2021
Full Text
View/download PDF

29. Association of local progression with deterioration of urinary symptoms and occurrence of genitourinary adverse events (AEs) in nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Post hoc analysis of PROSPER

Author

Grimm, M-O., primary, Hussain, M., additional, Stenzl, A., additional, Todenhöfer, T., additional, Haas, G.P., additional, Sugg, J., additional, Brauner, R., additional, Groß-Langenhoff, M., additional, and Sternberg, C.N., additional

Published
2021
Full Text
View/download PDF

31. Androgen receptor overexpression in prostate cancer in type 2 diabetes

Author

Lutz, S.Z., Hennenlotter, J., Scharpf, M.O., Sailer, C., Fritsche, L., Schmid, V., Kantartzis, K., Wagner, R., Lehmann, R., Berti, L., Peter, A., Staiger, H., Fritsche, A., Fend, A., Todenhöfer, T., Stenzl, A., Häring, H.-U., and Heni, M.

Subjects
Adult, Glutamate Carboxypeptidase II, Male, IGF-1 receptor, PSMA, prostate-specific membrane antigen, lcsh:Internal medicine, Cyp7B1, 25-hydroxycholesterol 7α-hydroxylase, DHT, dihydrotestosterone, ER, estrogen receptor, IR-A, insulin receptor isoform A, OGTT, oral glucose tolerance test, SERM, selective estrogen receptor modulator, Cytochrome P450 Family 7, ADT, androgen-deprivation therapy, Cyp27A1, SREBP2, sterol regulatory element-binding protein 2, Receptor, IGF Type 1, IGF1R, insulin like growth factor-1 receptor, Estrogen Receptor beta, Humans, lcsh:RC31-1245, Cyp7B1, Aged, Aged, 80 and over, PSA, prostate-specific antigen, Prostate cancer, Prostate, Prostatic Neoplasms, Middle Aged, Prostate-Specific Antigen, Insulin Receptor, Igf-1 Receptor, Cyp27a1, Cyp7b1 [Prostate Cancer, Androgen Receptor], Receptor, Insulin, Androgen receptor, Ki-67 Antigen, Diabetes Mellitus, Type 2, Receptors, Androgen, 27HC, 27-hydroxycholesterol, IR, insulin receptor, Antigens, Surface, Steroid Hydroxylases, Cyp27A1, sterol 27-hydroxylase, Cholestanetriol 26-Monooxygenase, Kallikreins, Original Article, AR, androgen receptor, IR-B, insulin receptor isoform B, Insulin receptor
Abstract

Objective While prostate cancer does not occur more often in men with diabetes, survival is markedly reduced in this patient group. Androgen signaling is a known and major driver for prostate cancer progression. Therefore, we analyzed major components of the androgen signaling chain and cell proliferation in relation to type 2 diabetes. Methods Tumor content of 70 prostate tissue samples of men with type 2 diabetes and 59 samples of patients without diabetes was quantified by an experienced pathologist, and a subset of 51 samples was immunohistochemically stained for androgen receptor (AR). mRNA expression of AR, insulin receptor isoform A (IR-A) and B (IR-B), IGF-1 receptor (IGF1R), Cyp27A1 and Cyp7B1, PSA gene KLK3, PSMA gene FOLH1, Ki-67 gene MKI67, and estrogen receptor beta (ESR2) were analyzed by RT-qPCR. Results AR mRNA and protein expression were associated with the tumor content only in men with diabetes. AR expression also correlated with downstream targets PSA (KLK3) and PSMA (FOLH1) and increased cell proliferation. Only in diabetes, AR expression was correlated to higher IR-A/IR-B ratio and lower IR-B/IGF1R ratio, thus, in favor of the mitogenic isoforms. Reduced Cyp27A1 and increased Cyp7B1 expressions in tumor suggest lower levels of protective estrogen receptor ligands in diabetes. Conclusions We report elevated androgen receptor signaling and activity presumably due to altered insulin/IGF-1 receptors and decreased levels of protective estrogen receptor ligands in prostate cancer in men with diabetes. Our results reveal new insights why these patients have a worse prognosis. These findings provide the basis for future clinical trials to investigate treatment response in patients with prostate cancer and diabetes., Highlights • Androgen receptor expression is elevated in prostate cancer in men with diabetes. • This correlates with altered IR and IGF-1R and protective estrogen receptor ligands. • Our results reveal new insights why these patients have worse prognosis.

Published
2018
Full Text
View/download PDF

32. 217O Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study

Author

Joshua, A.M., primary, Gurney, H., additional, Retz, M., additional, Tafreshi, A., additional, Fong, P.C.C., additional, Shore, N.D., additional, Romano, E., additional, Augustin, M., additional, Piulats, J.M., additional, Berry, W.R., additional, Kolinsky, M.P., additional, Sridhar, S.S., additional, Conter, H.J., additional, Todenhöfer, T., additional, Appleman, L.J., additional, Wu, H., additional, Schloss, C., additional, Poehlein, C.H., additional, de Bono, J.S., additional, and Yu, E.Y., additional

Published
2020
Full Text
View/download PDF

33. 621P Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update

Author

Arranz Arija, J.A., primary, Yu, E.Y., additional, Piulats, J.M., additional, Gravis, G., additional, Laguerre, B., additional, Oudard, S., additional, Fong, P.C., additional, Kolinsky, M.P., additional, Augustin, M., additional, Todenhöfer, T., additional, Kam, A.E., additional, Gurney, H., additional, Tafreshi, A., additional, Retz, M., additional, Berry, W.R., additional, Mar, N., additional, Wu, H., additional, Qiu, P., additional, Schloss, C., additional, and de Bono, J.S., additional

Published
2020
Full Text
View/download PDF

34. 625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update

Author

Mourey, L., primary, Conter, H.J., additional, Shore, N., additional, Berry, W.R., additional, Fong, P.C., additional, Piulats, J.M., additional, Appleman, L.J., additional, Todenhöfer, T., additional, Gravis, G., additional, Laguerre, B., additional, Gurney, H., additional, Retz, M., additional, Romano, E., additional, de Bono, J.S., additional, Kam, A.E., additional, Emmenegger, U., additional, Wu, H., additional, Qiu, P., additional, Schloss, C., additional, and Yu, E.Y., additional

Published
2020
Full Text
View/download PDF

38. Lebensqualität-adaptierte Zeit ohne Symptome oder Toxizität (Q-TWiST): Analyse von Cabozantinib (C) gegenüber Sunitinib (S) bei Patienten mit fortgeschrittenem Nierenzellkarzinom (aRCC) und intermediärem/hohem Risiko (Allianz A031203)

Author

Todenhöfer, T., Chen, R. C., Feuilly, M., Meng, J., Lister, J., Marteau, F., Morris, M. J., George, D. J., and Choueiri, T. K.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund: CABOSUN (NCT01835158), eine randomisierte, offene Phase-II-Studie, zeigte eine signifikante Verbesserung des progressionsfreien Überlebens mit C (8,6 Monate) gegenüber S (5,3 Monate) bei Erstlinientherapie von Patienten mit klarzelligem aRCC und intermediärem oder hohem Risiko.[zum vollständigen Text gelangen Sie über die oben angegebene URL], 60. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.

Published
2019

40. PCN502 RETROSPECTIVE GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY HEALTH INSURANCE)] STUDY ON INITIAL TREATMENT OF BLADDER CARCINOMA (BCA) BY TRANSURETHRAL BLADDER RESECTION (TURB) - A COMPARATIVE ANALYSIS OF COSTS AND UROLOGICAL FOLLOW-UP THERAPIES USING STANDARD WHITE LIGHT- (WL-) VS. BLUE LIGHT- (BL-)TURB

Author

Maas, M., primary, Stenzl, A., additional, Ketz, M., additional, Kossack, N., additional, Colling, C., additional, Qvick, B., additional, and Todenhöfer, T., additional

Published
2019
Full Text
View/download PDF

41. Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)

Author

Lavoie, J.-M., primary, Vandekerkhove, G., additional, Annala, M., additional, Taavitsainen, S., additional, Sundahl, N.L., additional, Walz, S., additional, Sano, T., additional, Khalaf, D., additional, Todenhöfer, T., additional, Ost, P., additional, Kollmannsberger, C.K., additional, Chi, K.N., additional, Black, P.C., additional, Wyatt, A.W., additional, and Eigl, B.J., additional

Published
2019
Full Text
View/download PDF

45. Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma

Author

Gakis, G., Morgan, T. M., Daneshmand, S., Keegan, K. A., Todenhöfer, T., Mischinger, J., Schubert, T., Zaid, H. B., Hrbacek, J., Ali-El-Dein, B., Clayman, R. H., Galland, S., Olugbade, K., Rink, M., Fritsche, H.-M, Burger, M., Chang, S. S., Babjuk, M., Thalmann, G. N., Stenzl, A., Efstathiou, J. A., Gakis, G., Morgan, T. M., Daneshmand, S., Keegan, K. A., Todenhöfer, T., Mischinger, J., Schubert, T., Zaid, H. B., Hrbacek, J., Ali-El-Dein, B., Clayman, R. H., Galland, S., Olugbade, K., Rink, M., Fritsche, H.-M, Burger, M., Chang, S. S., Babjuk, M., Thalmann, G. N., Stenzl, A., and Efstathiou, J. A.

Abstract

This is the first series that suggests a prognostic benefit of neoadjuvant treatment in a consecutive series of patients who underwent perioperative chemotherapy plus surgery for advanced primary urethral carcinoma. Further studies should yield a better understanding of how perioperative chemotherapy exerts a positive effect on survival in order to selectively advocate its use in advanced primary urethral carcinoma

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results